Endologix has announced the acquisition of the Pounce thrombectomy system from Surmodics. The transaction closed on 18 May 2026.
The Pounce system is a US Food and Drug Administration (FDA)-cleared, fully mechanical thrombectomy system for the non-surgical removal of thrombi and emboli from peripheral arteries. Built around proprietary dual-basket technology and a nitinol collection funnel, the system is designed to support procedural simplicity, versatility, and efficiency without reliance on capital equipment, thrombolytics, or aspiration, Endologix notes in a press release. The platform includes multiple commercially available configurations: Pounce LP, Pounce, and Pounce XL, designed to support use across a range of peripheral arterial vessel sizes, including smaller and more distal vessels.
Endologix states that the Pounce thrombectomy system will continue to be marketed in accordance with its existing FDA clearance during a transition period following the acquisition. A core group of Surmodics team members supporting Pounce will join Endologix as part of the transaction.
“I have used both Pounce and Endologix technologies in my practice, and bringing these solutions together under one organisation makes a great deal of clinical sense,” said Venkatesh Ramaiah (Pulse Cardiovascular Institute, Scottsdale, USA). “The Pounce fully mechanical thrombectomy system offers a grab-and-go solution that does not rely on thrombolytics or aspiration and complements Endologix’s portfolio of vascular technologies for the treatment of peripheral arterial disease. Together, these technologies provide physicians with additional flexibility when addressing thrombi and emboli in the peripheral arterial vasculature.”
